ClinicalTrials.gov
public full text
Public Domain
Trial to Evaluate Safety and Efficacy of GM-CSF /Sargramostim in Down Syndrome
This trial protocol is designed to evaluate primarily whether the use of sargramostim (recombinant human GM-CSF), administered five days per week for four consecutive weeks (20 treatment days), will be well tolerated by and safe for use in young adult participants with Down syndrome.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Post-marketing Surveillance on the Safety of CabometyxTM in Korean Patients#1150184
- Placebo Controlled Trial to Evaluate Zinc for the Treatment of COVID-19 in the Outpatient Setting#886491
- A Study to Assess the Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' RSV Investigational Vaccine (ChAd155-RSV) (GSK3389245A) in Healthy Adults#864729
- GISAR German Interdisciplinary Sarcoma Registry#801358
- Study to Evaluate the Safety, Tolerance and Immunogenicity of Fluviral™ in Healthy Adults#272432
Record · ID 801875
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive